The Schlage Sense Pro combines multiple new smart lock technologies and a cutting-edge design to make it one of the most ...

Clicks finally showed off the working Communicator software, and for anyone who misses physical keyboards, this first look is full of clever touches worth getting excited about.

We test Logitech's Signature Comfort Plus Combo MK880 to see if its comfortable design, customisable controls and low price ...

Forbes contributors publish independent expert analyses and insights. Technology journalist specializing in audio, computing and Apple Macs. This voice experience is generated by AI. Learn more. This ...

Insiders are buying after a brutal CSL share price fall. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member ...

CSL shares have been hammered by earnings disappointments. But the long-term investment case remains strong. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Wireless keyboards of all shapes and sizes are a great way to improve any PC gaming experience. While wired gaming keyboards are still preferred by most gamers, wireless gaming keyboards are quickly ...

If you buy something from a Verge link, Vox Media may earn a commission. See our ethics statement. is a senior editor and founding member of The Verge who covers gadgets, games, and toys. He spent 15 ...

We may receive a commission on purchases made from links. If you spend a lot of time typing emails, documents, or more recently, ChatGPT prompts, a good mechanical keyboard is an excellent investment.

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...